3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Multiple Myeloma
43
Leukemia, Myeloid, Acute
25
Recurrence
21
Lymphoma, Large B-Cell, Diffuse
12
Sarcoma
8
Neoplasms, Plasma Cell
5
Neoplasm Metastasis
5
Lymphoma
5
Glioblastoma
5
Ovarian Neoplasms
4
Neurofibrosarcoma
4
Neoplasms
4
Melanoma
4
Lymphoma, Non-Hodgkin
4
Endometrial Neoplasms
4
Colorectal Neoplasms
4
Triple Negative Breast Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Myelodysplastic Syndromes
3
Lymphoma, T-Cell, Peripheral
3
Lymphoma, Extranodal NK-T-Cell
3
Lymphoma, B-Cell
3
Liposarcoma
3
Glioma
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma
3
Waldenstrom Macroglobulinemia
2
Thymoma
2
Sarcoma, Alveolar Soft Part
2
Rhabdoid Tumor
2
Interventions
Cisplatin
178
Paclitaxel
79
Radiotherapy
76
Carboplatin
70
Brachytherapy
69
pembrolizumab
63
Bevacizumab
40
Gemcitabine
28
Radiation
27
Topotecan
26
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
25
Nivolumab
22
Colposcopy
22
human papillomavirus vaccine, L1 type 16, 18
21
Magnetic Resonance Spectroscopy
21
Drug Therapy
20
atezolizumab
19
Platinum
19
Papillomavirus Vaccines
18
Radiotherapy, Intensity-Modulated
17
Docetaxel
17
Taxes
16
Cyclophosphamide
16
Biopsy
16
Early Intervention, Educational
15
1,2-diaminocyclohexaneplatinum II citrate
15
Methods
14
Blood Specimen Collection
14
fludarabine
13
Injections
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Uterine Cervical Neoplasms
×
selinexor
×
Clear all
NCT02025985
2023-01-26
SIGN
Karyopharm Therapeutics Inc
Phase 2
Completed
116 enrolled
21 charts